Yazar "Wingerchuk, D. M." için listeleme

Toplam kayıt 6, listelenen: 1-6

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Pittock, S. J.; Berthele, A.; Fujihara, K.; Kim, H. J.; Levy, M.; Palace, J.; Wingerchuk, D. M. (Massachusetts Medical Soc, 2019)

Neuromyelitis optica spectrum disorder is a relapsing inflammatory disorder of the central nervous system. Two thirds of patients have antibodies against aquaporin-4, and CNS damage is complement dependent. The inhibitor ...
Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study

Palace, J.; Pittock, S. J.; Berthele, A.; Fujihara, K.; Kim, H. J.; Levy, M.; Wingerchuk, D. M. (Sage Publications Ltd, 2019)

…
Impact of eculizumab on hospitalization rates and relapse treatment in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study

Kim, H. J.; Pittock, S. J.; Berthele, A.; Fujihara, K.; Levy, M.; Palace, J.; Wingerchuk, D. M. (Sage Publications Ltd, 2019)

…
Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study

Berthele, A.; Pittock, S. J.; Fujihara, K.; Kim, H. J.; Levy, M.; Palace, J.; Wingerchuk, D. M. (Sage Publications Ltd, 2019)

…
Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder

Wingerchuk, D. M.; Pittock, S. J.; Berthele, A.; Fujihara, K.; Kim, H. J.; Levy, M.; Armstrong, R. (Sage Publications Ltd, 2019)

…
Subgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Pittock, S.; Berthele, A.; Fujihara, K.; Kim, H. J.; Levy, M.; Palace, J.; Wingerchuk, D. M. (Sage Publications Ltd, 2019)

…